Azilsartan medoxomil is an angiotensin II receptor adversary adumbrated for the analysis of balmy to abstinent capital hypertension. Azilsartan medoxomil is a prodrug of Azilsartan marketed as “Edarbi” by Takeda. Azilsartan medoxomil has so far been apparent to be above to olmesartan and valsartan in blurred claret pressure.
Azilsartan medoxomil is adumbrated for the analysis of hypertension in adults 18 years of age and older. It is accustomed for use abandoned or in aggregate with added antihypertensive drugs.
Azilsartan medoxomil is anatomize to the alive metabolite azilsartan in the GI tract. The attendance of aliment does not affect articulate assimilation of azilsartan medoxomil, and the bioavailability is 60% for azilsartan. Maximum claret concentrations are accomplished in 1.5 to 3 hours.